APOE and amyloidosis: In vivo administration of Ac-hE18A-NH2 to APP/PS1ΔE9 mice for six weeks improved cognition, decreased amyloid plaque deposition, reduced activated microglia and astrocytes, and increased CNS apoE levels [108].